Pfizer has signed a global licensing agreement with 3SBio to advance next-generation cancer therapies targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) pathways. Through the deal, valued at up to US$6 B, Pfizer gains rights outside of China to SSGJ-707, a bispecific antibody in development for the treatment of non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynaecological tumours. This partnership marks a significant step in Pfizer’s oncology strategy and underscores the growing global interest in dual-target immunotherapies for hard-to-treat cancers.